Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer

Papageorgiou, S, Pashley, SL, O’Regan, L et al. (3 more authors) (2022) Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers, 14 (14). 3452. ISSN 2072-6694

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
Keywords: EML4-ALK; NSCLC; ALK inhibitors; TKIs; chemotherapy; radiotherapy; immunotherapy; microtubule poisons
Dates:
  • Accepted: 12 July 2022
  • Published (online): 15 July 2022
  • Published: 15 July 2022
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 02 Aug 2022 13:49
Last Modified: 02 Aug 2022 13:49
Status: Published online
Publisher: MDPI
Identification Number: https://doi.org/10.3390/cancers14143452
Related URLs:

Export

Statistics